(Q38965866)

8 September 2017

title

Peptide receptor chemoradionuclide therapy in small cell carcinoma: from bench to bedside (English)

1 reference

8 September 2017

1 reference

Carleen Cullinane

2

0 references

Rodney J. Hicks

object named as

Rodney J Hicks

9

0 references

author name string

Jeremy Lewin

1

1 reference

8 September 2017

Tim Akhurst

3

1 reference

8 September 2017

Kelly Waldeck

4

1 reference

8 September 2017

D Neil Watkins

5

1 reference

8 September 2017

Aparna Rao

6

1 reference

8 September 2017

Peter Eu

7

1 reference

8 September 2017

Linda Mileshkin

8

1 reference

8 September 2017

publication date

16 August 2014

1 reference

8 September 2017

number of pages

8

1 reference

European Journal of Nuclear Medicine and Molecular Imaging

inferred from page(s)

published in

1 reference

8 September 2017

volume

42

1 reference

8 September 2017

issue

1

1 reference

8 September 2017

page(s)

25-32

1 reference

https://scigraph.springernature.com/pub.10.1007/s00259-014-2888-2

8 September 2017

exact match

0 references

cites work

Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2888-2

Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multi-institutional retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2888-2

A systematic analysis of efficacy of second-line chemotherapy in sensitive and refractory small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2888-2

Clinical and therapeutic aspects of extrapulmonary small cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2888-2

Somatostatin receptors are present in small-cell but not in non-small-cell primary lung carcinomas: relationship to EGF-receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2888-2

Gene expression of somatostatin receptor subtypes, SSTR1 and SSTR2, in human lung cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2888-2

Experimental and clinical studies with somatostatin analogue octreotide in small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2888-2

High affinity binding of [125I-Tyr11]somatostatin-14 to human small cell lung carcinoma (NCI-H69).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2888-2

Binding of TS1, an anti-keratin 8 antibody, in small-cell lung cancer after 177Lu-DOTA-Tyr3-octreotate treatment: a histological study in xenografted mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2888-2

Brief report on the use of radiolabeled somatostatin analogs for the diagnosis and treatment of metastatic small-cell lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2888-2

Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2888-2

Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2888-2

Targeted radiotherapy for small cell lung cancer using 90Yttrium-DOTATOC, an Yttrium-labelled somatostatin analogue: a pilot trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2888-2

High-administered activity In-111 octreotide therapy with concomitant radiosensitizing 5FU chemotherapy for treatment of neuroendocrine tumors: preliminary experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2888-2

177Lu-octreotate, alone or with radiosensitising chemotherapy, is safe in neuroendocrine tumour patients previously treated with high-activity 111In-octreotide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2888-2

A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2888-2

Rapid blood clearance and lack of long-term renal toxicity of 177Lu-DOTATATE enables shortening of renoprotective amino acid infusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2888-2

The tumour sink effect on the biodistribution of 68Ga-DOTA-octreotate: implications for peptide receptor radionuclide therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2888-2

Differential (18)F-FDG and 3'-deoxy-3'-(18)F-fluorothymidine PET responses to pharmacologic inhibition of the c-MET receptor in preclinical tumor models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2888-2

A crucial requirement for Hedgehog signaling in small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2888-2

Detection of somatostatin receptor subtype 2 (SSTR2) in established tumors and tumor cell lines: evidence for SSTR2 heterogeneity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2888-2

Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2888-2

Long acting somatostatin analogues in combination to antineoplastic agents in the treatment of small cell lung cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2888-2

Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2888-2

Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma

21 January 2018

1 reference

12 December 2020

Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trial

1 reference

12 December 2020

Single photon emission computed tomography procedure improves accuracy of somatostatin receptor scintigraphy in gastro-entero pancreatic tumours

1 reference

12 December 2020

Phase II study of high-dose somatostatin analogue in patients either previously treated or untreated who have extensive-stage small cell lung cancer

1 reference

12 December 2020

Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer

1 reference

12 December 2020

Processing of generator-produced 68Ga for medical application.

1 reference

12 December 2020

DNA repair and cell cycle interactions in radiation sensitization by the topoisomerase II poison etoposide.

1 reference

12 December 2020

10.1007/S00259-014-2888-2

Identifiers

DOI

1 reference

8 September 2017

1 reference